Skip to main content
SpringerLink
Log in

Co-resistance to ceftazidime-avibactam and cefiderocol in clinical isolates producing KPC variants

  • Brief Report
  • Published:
European Journal of Clinical Microbiology & Infectious Diseases Aims and scope Submit manuscript

Abstract

Cefiderocol (FDC) and ceftazidime-avibactam (CZA) are among the latest generation of commercialized antibiotics against carbapenem-resistant Gram negatives. However, emergence of CZA resistance is being increasingly reported, involving different KPC variants in Enterobacterales. By analyzing two CZA-resistant KPC-3 clinical variants, KPC-41 and KPC-50, we showed that KPC-41, and to a lesser extent KPC-50, may also have an impact on susceptibility to FDC leading to a cross-resistance. This feature highlights that a susceptibility testing to FDC is mandatory prior any clinical use of FDC for treating infections due to KPC producers.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Munoz-Price LS, Poirel L, Bonomo RA et al (2013) Clinical epidemiology of the global expansion of Klebsiella pneumoniae carbapenemases. Lancet Infect Dis 13(9):785–796. https://doi.org/10.1016/S1473-3099(13)70190-7

    Article  PubMed  PubMed Central  Google Scholar 

  2. Kazmierczak KM, Biedenbach DJ, Hackel M et al (2016) Global dissemination of blaKPC into bacterial species beyond Klebsiella pneumoniae and in vitro susceptibility to ceftazidime-avibactam and aztreonam-avibactam. Antimicrob Agents Chemother 60(8):4490–4500. https://doi.org/10.1128/AAC.00107-16

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Zhanel GG, Lawson CD, Adam H et al (2013) Ceftazidime-avibactam: a novel cephalosporin/β-lactamase inhibitor combination. Drugs 73(2):159–177. https://doi.org/10.1007/s40265-013-0013-7

    Article  CAS  PubMed  Google Scholar 

  4. Sharma R, Park TE, Moy S (2016) Ceftazidime-avibactam: a novel cephalosporin/β-lactamase inhibitor combination for the treatment of resistant Gram-negative organisms. Clin Ther 38(3):431–444. https://doi.org/10.1016/j.clinthera.2016.01.018

    Article  CAS  PubMed  Google Scholar 

  5. Barnes MD, Winkler ML, Taracila MA et al (2017) Klebsiella pneumoniae carbapenemase-2 (KPC-2), substitutions at ambler position Asp179, and resistance to ceftazidime-avibactam: unique antibiotic-resistant phenotypes emerge from β-lactamase protein engineering. MBio 8(5):e00528-e617. https://doi.org/10.1128/mBio.00528-17

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Hemarajata P, Humphries RM (2019) Ceftazidime/avibactam resistance associated with L169P mutation in the omega loop of KPC-2. J Antimicrob Chemother 74(5):1241–1243. https://doi.org/10.1093/jac/dkz026

    Article  CAS  PubMed  Google Scholar 

  7. Di Pilato V, Aiezza N, Viaggi V et al (2020) KPC-53, a KPC-3 Variant of clinical origin associated with reduced susceptibility to ceftazidime-avibactam. Antimicrob Agents Chemother 65(1):e01429-e1520. https://doi.org/10.1128/AAC.01429-20

    Article  PubMed  PubMed Central  Google Scholar 

  8. Livermore DM, Warner M, Jamrozy D et al (2015) In vitro selection of ceftazidime-avibactam resistance in Enterobacteriaceae with KPC-3 carbapenemase. Antimicrob Agents Chemother 59(9):5324–5330. https://doi.org/10.1128/AAC.00678-15

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Shields RK, Chen L, Cheng S et al (2017) Emergence of ceftazidime-avibactam resistance due to plasmid-borne blaKPC-3 mutations during treatment of carbapenem-resistant Klebsiella pneumoniae infections. Antimicrob Agents Chemother 61(3):e02097-e2116. https://doi.org/10.1128/AAC.02097-16

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Shields RK, Nguyen MH, Chen L et al (2018) Pneumonia and renal replacement therapy are risk factors for ceftazidime-avibactam treatment failures and resistance among patients with carbapenem-resistant Enterobacteriaceae infections. Antimicrob Agents Chemother 62(5):e02497-e2517. https://doi.org/10.1128/AAC.02497-17

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Venditti C, Nisii C, D’Arezzo S et al (2019) Molecular and phenotypical characterization of two cases of antibiotic-driven ceftazidime-avibactam resistance in blaKPC-3-harboring Klebsiella pneumoniae. Infect Drug Resist 12:1935–1940. https://doi.org/10.2147/IDR.S207993

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Mueller L, Masseron A, Prod’Hom G et al (2019) Phenotypic, biochemical and genetic analysis of KPC-41, a KPC-3 variant conferring resistance to ceftazidime-avibactam and exhibiting reduced carbapenemase activity. Antimicrob Agents Chemother 63(12):e01111-e1119. https://doi.org/10.1128/AAC.01111-19

    Article  CAS  PubMed Central  Google Scholar 

  13. Poirel L, Vuillemin X, Juhas M et al (2020) KPC-50 confers resistance to ceftazidime-avibactam associated with reduced carbapenemase activity. Antimicrob Agents Chemother 64(8):e00321-e420. https://doi.org/10.1128/AAC.00321-20

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Findlay J, Poirel L, Juhas M, Nordmann P (2021) KPC-mediated resistance to ceftazidime-avibactam and collateral effects in Klebsiella pneumoniae. Antimicrob Agents Chemother 65(9):e0089021. https://doi.org/10.1128/AAC.00890-21

    Article  PubMed  Google Scholar 

  15. Kohira N, West J, Ito A et al (2015) In vitro antimicrobial activity of a siderophore cephalosporin, S-649266, against enterobacteriaceae clinical isolates, including carbapenem-resistant strains. Antimicrob Agents Chemother 60(2):729–734. https://doi.org/10.1128/AAC.01695-15

    Article  CAS  PubMed  Google Scholar 

  16. Hackel MA, Tsuji M, Yamano Y et al (2018) In vitro activity of the siderophore cephalosporin, cefiderocol, against carbapenem-nonsusceptible and multidrug-resistant isolates of Gram-negative bacilli collected worldwide in 2014 to 2016. Antimicrob Agents Chemother 62(2):e01968-e2017. https://doi.org/10.1128/AAC.01968-17

    Article  PubMed  PubMed Central  Google Scholar 

  17. Sato T, Yamawaki K (2019) Cefiderocol: discovery, chemistry, and in vivo profiles of a novel siderophore cephalosporin. Clin Infect Dis 69(Suppl 7):S538–S543. https://doi.org/10.1093/cid/ciz826

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Kohira N, Hackel MA, Ishioka Y et al (2020) Reduced susceptibility mechanism to cefiderocol, a siderophore cephalosporin, among clinical isolates from a global surveillance programme (SIDERO-WT-2014). J Glob Antimicrob Resist 22:738–741. https://doi.org/10.1016/j.jgar.2020.07.009

    Article  PubMed  Google Scholar 

  19. Poirel L, Sadek M, Nordmann P (2021) Contribution of PER-type and NDM-type β-lactamases to cefiderocol resistance in Acinetobacter baumannii. Antimicrob Agents Chemother 65(10):e0087721. https://doi.org/10.1128/AAC.00877-21

    Article  PubMed  Google Scholar 

  20. Hobson CA, Cointe A, Jacquier H et al (2021) Cross-resistance to cefiderocol and ceftazidime-avibactam in KPC β-lactamase mutants and the inoculum effect. Clin Microbiol Infect 27(8):1172.e7-1172.e10. https://doi.org/10.1016/j.cmi.2021.04.016

    Article  CAS  Google Scholar 

  21. EUCAST (2021) The European Committee on antimicrobial susceptibility testing breakpoint tables for interpretation of MICs and zone diameters, version v11.0. 2021.https://www.eucast.org/fileadmin/src/media/PDFs/EUCAST_files/Breakpoint_tables/v_11.0_Breakpoint_Tables.pdf.

  22. Poirel L, Ortiz de la Rosa JM, Richard A, Aires-de-Sousa M, Nordmann P (2019) CTX-M-33, a CTX-M-15 derivative conferring reduced susceptibility to carbapenems. Antimicrob Agents Chemother 63(12):e01515-e1519. https://doi.org/10.1128/AAC.01515-19

    Article  CAS  PubMed Central  Google Scholar 

  23. Ito A, Sato T, Ota M et al (2017) In vitro antibacterial properties of cefiderocol, a novel siderophore cephalosporin, against Gram-negative bacteria. Antimicrob Agents Chemother 62(1):e01454-e1517. https://doi.org/10.1128/AAC.01454-17

    Article  PubMed  PubMed Central  Google Scholar 

  24. Bianco G, Boattini M, Comini S et al (2021) In vitro activity of cefiderocol against ceftazidime-avibactam susceptible and resistant KPC-producing Enterobacterales: cross-resistance and synergistic effects [published online ahead of print, 2021 Aug 31]. Eur J Clin Microbiol Infect Dis. https://doi.org/10.1007/s10096-021-04341-z

  25. Tiseo G, Falcone M, Leonildi A et al (2021) Meropenem-vaborbactam as salvage therapy for ceftazidime-avibactam-, cefiderocol-resistant ST-512 Klebsiella pneumoniae-producing KPC-31, a D179Y variant of KPC-3. Open Forum Infect Dis 8(6):ofab141. https://doi.org/10.1093/ofid/ofab141

Download references

Funding

This work was financed by the University of Fribourg, Switzerland, the NARA, and by the Swiss National Science Foundation (grant FNS 310030_1888801).

Author information

Authors and Affiliations

  1. Medical and Molecular Microbiology Unit, Department of Medicine, Faculty of Science, University of Fribourg, Chemin du Musée 18, CH-1700, Fribourg, Switzerland

    Laurent Poirel, Mustafa Sadek, Ayda Kusaksizoglu & Patrice Nordmann

  2. INSERM European Unit (IAME), University of Fribourg, Fribourg, Switzerland

    Laurent Poirel & Patrice Nordmann

  3. Swiss National Reference Center for Emerging Antibiotic Resistance (NARA), University of Fribourg, Fribourg, Switzerland

    Laurent Poirel & Patrice Nordmann

  4. Department of Food Hygiene and Control, Faculty of Veterinary Medicine, South Valley University, Qena, 83523, Egypt

    Mustafa Sadek

  5. Institute for Microbiology, University of Lausanne and University Hospital Centre, Lausanne, Switzerland

    Patrice Nordmann

Authors
  1. Laurent Poirel
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Mustafa Sadek
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ayda Kusaksizoglu
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Patrice Nordmann
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Patrice Nordmann.

Additional information

Publisher's note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Poirel, L., Sadek, M., Kusaksizoglu, A. et al. Co-resistance to ceftazidime-avibactam and cefiderocol in clinical isolates producing KPC variants. Eur J Clin Microbiol Infect Dis 41, 677–680 (2022). https://doi.org/10.1007/s10096-021-04397-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10096-021-04397-x

Keywords

Search

Navigation